nodes	percent_of_prediction	percent_of_DWPC	metapath
Niflumic Acid—PTGS2—bone cancer	0.406	1	CbGaD
Niflumic Acid—PLA2G4A—Epirubicin—bone cancer	0.38	0.658	CbGbCtD
Niflumic Acid—SLC16A1—Methotrexate—bone cancer	0.137	0.238	CbGbCtD
Niflumic Acid—PTGS2—Cisplatin—bone cancer	0.0597	0.104	CbGbCtD
Niflumic Acid—PLA2G4A—Raltitrexed—Methotrexate—bone cancer	0.00384	1	CbGdCrCtD
Niflumic Acid—Floctafenine—PTGS2—bone cancer	0.00149	0.719	CrCbGaD
Niflumic Acid—Mefenamic acid—PTGS2—bone cancer	0.000583	0.281	CrCbGaD
Niflumic Acid—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.00049	0.0423	CbGpPWpGaD
Niflumic Acid—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNA11—bone cancer	0.00041	0.0354	CbGpPWpGaD
Niflumic Acid—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.000406	0.0351	CbGpPWpGaD
Niflumic Acid—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.000401	0.0346	CbGpPWpGaD
Niflumic Acid—CLCNKA—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000392	0.0339	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signal amplification—GNA11—bone cancer	0.000345	0.0298	CbGpPWpGaD
Niflumic Acid—CLCNKA—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000339	0.0292	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.000329	0.0284	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000291	0.0252	CbGpPWpGaD
Niflumic Acid—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000253	0.0218	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—GNA11—bone cancer	0.000196	0.0169	CbGpPWpGaD
Niflumic Acid—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.000185	0.016	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000184	0.0159	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000177	0.0153	CbGpPWpGaD
Niflumic Acid—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000177	0.0153	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	0.00016	0.0138	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000159	0.0137	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000156	0.0135	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000142	0.0123	CbGpPWpGaD
Niflumic Acid—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000139	0.012	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000126	0.0109	CbGpPWpGaD
Niflumic Acid—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000115	0.00993	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000115	0.00989	CbGpPWpGaD
Niflumic Acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000114	0.00983	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000114	0.0098	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—NDUFA12—bone cancer	0.000105	0.00904	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGF Pathway—JUN—bone cancer	0.000104	0.00899	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000104	0.00896	CbGpPWpGaD
Niflumic Acid—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000101	0.00873	CbGpPWpGaD
Niflumic Acid—UGT1A9—Phase II conjugation—GSTP1—bone cancer	9.63e-05	0.00832	CbGpPWpGaD
Niflumic Acid—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	9.62e-05	0.00831	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Arachidonic acid metabolism—PTGS2—bone cancer	9.47e-05	0.00817	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP2—bone cancer	8.85e-05	0.00764	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	8.82e-05	0.00761	CbGpPWpGaD
Niflumic Acid—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	8.68e-05	0.0075	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—NT5C3A—bone cancer	8.68e-05	0.00749	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.03e-05	0.00693	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—SPARC—bone cancer	7.85e-05	0.00678	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.84e-05	0.00677	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.56e-05	0.00653	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	7.5e-05	0.00647	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.31e-05	0.00631	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	7.28e-05	0.00629	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.21e-05	0.00623	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—GNA11—bone cancer	7.18e-05	0.0062	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	7.1e-05	0.00613	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—JUN—bone cancer	7.1e-05	0.00613	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	7.08e-05	0.00611	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—JUN—bone cancer	6.84e-05	0.0059	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.77e-05	0.00584	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP9—bone cancer	6.65e-05	0.00574	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	6.6e-05	0.0057	CbGpPWpGaD
Niflumic Acid—UGT1A9—Biological oxidations—CYP3A4—bone cancer	6.59e-05	0.00569	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—IL3—bone cancer	6.51e-05	0.00562	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	6.5e-05	0.00561	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	6.43e-05	0.00555	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—GSTP1—bone cancer	6.43e-05	0.00555	CbGpPWpGaD
Niflumic Acid—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	6.4e-05	0.00552	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—NDUFA12—bone cancer	6.13e-05	0.00529	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.11e-05	0.00528	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	6.09e-05	0.00526	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.94e-05	0.00513	CbGpPWpGaD
Niflumic Acid—UGT1A9—Biological oxidations—GSTP1—bone cancer	5.64e-05	0.00487	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—BRAF—bone cancer	5.63e-05	0.00486	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	5.56e-05	0.0048	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	5.56e-05	0.0048	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—EGFR—bone cancer	5.37e-05	0.00464	CbGpPWpGaD
Niflumic Acid—PTGS1—Biological oxidations—CYP3A4—bone cancer	5.37e-05	0.00464	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—SPARC—bone cancer	5.2e-05	0.00449	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—NT5C3A—bone cancer	5.08e-05	0.00439	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—NDUFA12—bone cancer	4.77e-05	0.00412	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—GNA11—bone cancer	4.76e-05	0.00411	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	4.73e-05	0.00408	CbGpPWpGaD
Niflumic Acid—PTGS1—Biological oxidations—GSTP1—bone cancer	4.59e-05	0.00397	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	4.58e-05	0.00395	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.53e-05	0.00391	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—KIT—bone cancer	4.42e-05	0.00381	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—IL3—bone cancer	4.31e-05	0.00372	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.31e-05	0.00372	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—JUN—bone cancer	4.1e-05	0.00354	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	4.07e-05	0.00351	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—SPARC—bone cancer	4.05e-05	0.00349	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	4.02e-05	0.00347	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—NT5C3A—bone cancer	3.95e-05	0.00341	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—NDUFA12—bone cancer	3.95e-05	0.00341	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	3.92e-05	0.00339	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	3.87e-05	0.00334	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	3.85e-05	0.00332	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—ENO2—bone cancer	3.8e-05	0.00328	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—RGS1—bone cancer	3.8e-05	0.00328	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—GRM4—bone cancer	3.8e-05	0.00328	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—GNA11—bone cancer	3.7e-05	0.00319	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—CDK4—bone cancer	3.57e-05	0.00309	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—DHFR—bone cancer	3.53e-05	0.00305	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.36e-05	0.0029	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—IL3—bone cancer	3.35e-05	0.0029	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—GNA11—bone cancer	3.3e-05	0.00285	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—GRM1—bone cancer	3.3e-05	0.00285	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.28e-05	0.00283	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—NT5C3A—bone cancer	3.27e-05	0.00283	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.24e-05	0.0028	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—NDUFA12—bone cancer	3.22e-05	0.00278	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—RB1—bone cancer	3.11e-05	0.00268	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—CYP3A4—bone cancer	2.99e-05	0.00258	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.97e-05	0.00257	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.92e-05	0.00252	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—PLAU—bone cancer	2.83e-05	0.00244	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—NT5C3A—bone cancer	2.67e-05	0.0023	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—NDUFA12—bone cancer	2.56e-05	0.00221	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—GSTP1—bone cancer	2.56e-05	0.00221	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.43e-05	0.0021	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—SMO—bone cancer	2.32e-05	0.002	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.3e-05	0.00198	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—RGS1—bone cancer	2.25e-05	0.00194	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GRM4—bone cancer	2.25e-05	0.00194	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MMP9—bone cancer	2.24e-05	0.00193	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—ENO2—bone cancer	2.22e-05	0.00192	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—PLAU—bone cancer	2.2e-05	0.0019	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—GNA11—bone cancer	2.12e-05	0.00183	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—NT5C3A—bone cancer	2.12e-05	0.00183	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—DHFR—bone cancer	2.06e-05	0.00178	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GRM1—bone cancer	1.95e-05	0.00168	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—GNA11—bone cancer	1.93e-05	0.00167	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.93e-05	0.00167	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL3—bone cancer	1.93e-05	0.00166	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—EGFR—bone cancer	1.81e-05	0.00156	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.8e-05	0.00156	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—CYP3A4—bone cancer	1.75e-05	0.00151	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—ENO2—bone cancer	1.73e-05	0.00149	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—DHFR—bone cancer	1.61e-05	0.00139	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.57e-05	0.00135	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TP53—bone cancer	1.52e-05	0.00131	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—GNA11—bone cancer	1.5e-05	0.0013	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—GSTP1—bone cancer	1.5e-05	0.00129	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—ENO2—bone cancer	1.43e-05	0.00124	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SMO—bone cancer	1.37e-05	0.00118	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—CYP3A4—bone cancer	1.36e-05	0.00117	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.35e-05	0.00117	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—DHFR—bone cancer	1.33e-05	0.00115	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PTGS2—bone cancer	1.32e-05	0.00114	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GNA11—bone cancer	1.25e-05	0.00108	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GNA11—bone cancer	1.24e-05	0.00107	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.23e-05	0.00106	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—ENO2—bone cancer	1.17e-05	0.00101	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ATF1—bone cancer	1.17e-05	0.00101	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—GSTP1—bone cancer	1.16e-05	0.001	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TP53—bone cancer	1.14e-05	0.000982	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL3—bone cancer	1.14e-05	0.000982	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CYP3A4—bone cancer	1.13e-05	0.000973	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.12e-05	0.000968	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ENO2—bone cancer	1.11e-05	0.000956	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—DHFR—bone cancer	1.08e-05	0.000936	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.03e-05	0.000893	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—DHFR—bone cancer	1.03e-05	0.000887	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GNA11—bone cancer	1.01e-05	0.000875	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TGFBR2—bone cancer	9.73e-06	0.00084	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GSTP1—bone cancer	9.64e-06	0.000832	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—ENO2—bone cancer	9.28e-06	0.000801	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP3A4—bone cancer	9.19e-06	0.000793	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IGF1R—bone cancer	9.15e-06	0.00079	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.14e-06	0.000789	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TP53—bone cancer	8.85e-06	0.000764	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—DHFR—bone cancer	8.61e-06	0.000743	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GNA11—bone cancer	8.04e-06	0.000695	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GSTP1—bone cancer	7.86e-06	0.000678	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PTGS2—bone cancer	7.75e-06	0.000669	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TGFBR2—bone cancer	7.45e-06	0.000643	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP3A4—bone cancer	7.29e-06	0.00063	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KIT—bone cancer	6.64e-06	0.000573	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—BRAF—bone cancer	6.24e-06	0.000539	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GSTP1—bone cancer	6.24e-06	0.000539	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—EGFR—bone cancer	6.05e-06	0.000522	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PTGS2—bone cancer	6.03e-06	0.00052	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MDM2—bone cancer	5.23e-06	0.000451	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—KIT—bone cancer	5.08e-06	0.000439	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PTGS2—bone cancer	4.99e-06	0.000431	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—BRAF—bone cancer	4.78e-06	0.000412	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—JUN—bone cancer	4.54e-06	0.000392	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MMP9—bone cancer	4.42e-06	0.000382	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PTGS2—bone cancer	4.07e-06	0.000351	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MDM2—bone cancer	4e-06	0.000346	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—EGFR—bone cancer	3.57e-06	0.000308	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TP53—bone cancer	3e-06	0.000259	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—EGFR—bone cancer	2.74e-06	0.000236	CbGpPWpGaD
